Table 3.
Published results with large-diameter (≥ 36 mm) metal-on-metal THA
| Study | Device (patient factors) | Number of THAs | Mean followup (years) | Dislocations | Bearing survival (number revised) | ARMD incidence or mean ion levels |
|---|---|---|---|---|---|---|
| Cuckler et al., 2004 [12] | M2a-38 | 616 | 1 (0–2) | 0 (0%) | 100% (0) | 0 (0%) |
| Stuchin, 2008 [59] | Birmingham | 34 | 1 | 0 (0%) | 100% (0) | 0 (0%) |
| Parmaksizoglu et al., 2009 [51] | Magnum™ (Crowe IV DDH) | 15 | 4 (3–5) | 0 (0%) | 100% (0) | 0 (0%) |
| Berton et al., 2010 [7] | Durom | 100 | 5 | 0 (0%) | 93% (7) | 0 (0%) |
| Cicek et al., 2010 [10] | Cormet/Optimom | 54 | 4 | 0 (0%) | 98% (1) | 0 (0%) |
| Illgen et al., 2010 [24] | Durom | 63 | 1 | 0 (0%) | 89% (7) | 1 (2%) |
| Long et al., 2010 [40] | Durom | 207 | 2 (1–2) | 1 (1%) | 86% (30) | 0 (0%) |
| Mertl et al., 2010 [45] | Durom | 106 | 3 | 2 (2%) | 100% (0) | 0 (0%) |
| Zhang et al., 2010 [67] | 25 Durom, 34 ASR (elderly) | 59 | 5 | 0 (0%) | 100% (0) | 0 (0%) |
| de Steiger et al., 2011 [13] | ASR | 4406 | 2–7 | 15 (0%) | 95% (210) | 26 (1%) |
| Bolland et al., 2011 [8] | Birmingham | 199 | 5 (3–7) | 0 (0%) | 92% (17) | 14 (7%) |
| Graves et al., 2011 [16] | ASR | N/A (combined from Australian, England and Wales, and New Zealand registries) |
N/A | N/A | 92% at 5 years | N/A |
| Ultamet/ArticulEze | 97% at 5 years | |||||
| Birmingham | 95% at 5 years | |||||
| R3 | 98% at 1 year | |||||
| Bionik | 92% at 3 years | |||||
| Cormet | 93% at 5 years | |||||
| Icon | 94% at 3 years | |||||
| M2a-38 | 95% at 5 years | |||||
| Magnum™ | 98% at 3 years | |||||
| Durom | 95% at 5 years | |||||
| Mitch TRH | 99% at 1 year | |||||
| Ultamet/S-ROM | 96% at 5 years | |||||
| Langton et al., 2011 [31] | ASR | 87 | 6 | N/A | 51% at 6 years | 25 (29%) |
| Lavigne et al., 2011 [34] | Durom | 49 | 2 | N/A | 98% (1) | 3 µg/L mean blood Co |
| Magnum™ | 19 | 2 | 100% (0) | 1 µg/L mean blood Co | ||
| ASR | 10 | 2 | 100% (0) | 1 µg/L mean blood Co | ||
| Birmingham | 11 | 2 | 100% (0) | 2 µg/L mean blood Co | ||
| Malviya et al., 2011 [42] | Birmingham | 50 | 2 | 0 (0%) | 96% (2) | 2 (4%) |
| Steele et al., 2011 [58] | ASR | 105 | 2 (0–3) | 0 (0%) | 85% (16) | 4 (4%) |
| Wynn-Jones et al., 2011 [65] | ASR | 62 | 3 (1–4) | 0 (0%) | 87% (8) | 6 (10%) |
| Yalcin et al., 2011 [66] | Cormet/Optimom (Crowe I and II DDH) | 75 | 5 (3–6) | 0 (0%) | 100% (0) | 0 (0%) |
| Althuizen et al., 2012 [1] | Durom | 64 | 3 | 0 (0%) | 86% (6) | 3 (5%) |
| Barrett et al., 2012 [5] | Pinnacle/Ultamet | 779 | 4 (2–10) | 3 (0%) | 97% (21) | 7 (1%) |
| Bernthal et al., 2012 [6] | ASR | 70 | (2–5) | 0 (0%) | 83% (12) | 0 (0%) |
| Bosker et al., 2012 [9] | Magnum™ | 108 | 4 (3–5) | 0 (0%) | 88% (13) | 42 (39%) |
| Hasegawa et al., 2012 [19] | Cormet | 75 | 2 | 0 (0%) | 97% (2) | 2 (3%) |
| Hutt et al., 2012 [23] | Durom | 84 | 4 (2–7) | 0 (0%) | 95% (4) | 0 (0%) |
| Kindsfater et al., 2012 [27] | Pinnacle/Ultamet | 85 | 6 (5–8) | 2 (2%) | 99% (1) | 0 (0%) |
| Kostensalo et al., 2012 [29] | Magnum™ | 691 | 1 | 0 (0%) | 98% (11) | 0 (0%) |
| Lardanchet et al., 2012 [32] | Durom | 24 | 1 | 1 (4%) | 92% (2) | 3 µg/L mean serum Co |
| Magnum™ | 23 | 1 (4%) | 100% (0) | 2 µg/L mean serum Co | ||
| Conserve | 20 | 0 (0%) | 100% (0) | 8 µg/L mean serum Co | ||
| Meding et al., 2012 [44] | Magnum™ | 611 | 3 (2–5) | 1 (0%) | 100% (3) | 0 (0%) |
| Stürup et al., 2012 [60] | 85 M2a-38, 271 Magnum™ | 358 | 4 (1–6) | 1 (0%) | 95% (17) | 1 (0%) |
| Hasegawa et al., 2013 [20] | Cormet | 108 | 2 | 0 (0.0%) | 94% (7) | 12 (11%) |
| Hosny et al., 2013 [22] | Birmingham | 44 | 5 | 1 (2.3%) | 93% (3) | 2 (5%) |
| Jack et al., 2013 [25] | Birmingham | 2101 | (0–6) | N/A | 95% at 5 years (50) | N/A |
| Levy and Ezzet, 2013 [35] | Conserve | 66 | 2 | 0 (0%) | 86% (9) | 8/78 |
| Dynasty | 12 | 2 | 0 (0%) | 92% (1) | (10%) | |
| Mokka et al., 2013 [47] | Magnum™ | 80 | 6 (5–7) | N/A | 96% (3) | 43 (54%) |
| Mokka et al., 2013 [46] | Birmingham | 432 | 3 (0–6) | N/A | 98% at 5 years | n/a |
| ASR/Summit | 495 | 2 (0–6) | 97% at 5 years | |||
| Magnum™ | 4202 | 2 (0–5) | 97% at 5 years | |||
| Durom/CLS | 154 | 4 (1–5) | 89% at 5 years | |||
| M2a-38 | 2459 | 4 (0–8) | 96% at 7 years | |||
| ASR/Corail | 120 | 2 (0–4) | 97% at 3 years | |||
| Durom/ML-taper | 197 | 1 (0–4) | N/A | |||
| Junnila et al., 2014 [26] | Magnum™ | 5464 | 3 (0–7) | N/A | 97% at 4 years | N/A |
| Birmingham | 475 | 4 (0–8) | 97% at 4 years | |||
| ASR | 632 | 4 (0–8) | 90% at 4 years | |||
| Park et al., 2014 [50] | Magnum™ (neuromuscular weakness) | 19 | 1 | 0 (0%) | 100% (0) | 0 (0%) |
| Sugano et al., 2014 [61] | Pinnacle Ultamet* | 4744 | N/A (surgeries done 2000 to 2011 in Japan) | N/A | N/A | 63 (1%) |
| Conserve | 1701 | 37 (2%) | ||||
| Cormet | 491 | 15 (3%) | ||||
| Adept | 636 | 7 (1%) | ||||
| M2a-Taper, Magnum™* | 2777 | 24 (1%) | ||||
| FMP* | 956 | 4 (0%) | ||||
| Birmingham | 121 | 0 (0%) | ||||
| Current study | M2a-38 | 636 | 8 | 1 (0%) | 91% (59) | 28 (4%) |
| Magnum™ | ||||||
| 804 | ||||||
| 6 | 0 (0%) | 94% (49) | 19 (1%) |
*Some smaller head sizes included; ARMD = adverse reaction to metal debris; DDH = developmental dysplasia; ASR = Articular Surface Replacement; N/A = not available; Co = cobalt. Manufacturers: M2a-38, Magnum (Biomet, Inc, Warsaw, IN, USA; Valance, France); Birmingham, R3 (Smith & Nephew, Memphis, TN, USA; Warwick, UK; London, UK; Hull, UK); Cormet (Corin Medical Ltd, Cirencester, UK); Durom, CLS, ML-Taper (Zimmer, Inc, Warsaw, IN, USA; Winterthur, Switzerland; Etupes, France); ASR, Pinnacle Ultamet, ArticulEze, S-ROM, Summit, Corail (DePuy, Inc, Warsaw, IN, USA; Leeds, UK); Bionik (Orthodynamics, Lübeck, Germany), Icon (International Orthopaedics, Geisingen, Germany); Mitch TRH (Stryker, Mahwah, NJ, USA); Conserve, Dynasty (Wright Medical Technology, Arlington, TN, USA; Rueil Malmaison, France), FMP (DJO Surgical, Vista, CA, USA).